Adherence to Varenicline and Abstinence Rates for Quitting Smoking in a Private Health Promotion Center-Based Smoking Cessation Clinic |
Lee, Jin-Young
(Center for Health Promotion, Samsung Medical Center)
Kim, Min-Ji (Biostatistics Unit, Samsung Biomedical Research Institute, Samsung Medical Center) Jun, Hee-Jung (Center for Health Promotion, Samsung Medical Center) Kang, Mi-Ra (Center for Health Promotion, Samsung Medical Center) Park, Ah-Rham (Center for Health Promotion, Samsung Medical Center) Oh, Dae-Eun (Center for Health Promotion, Samsung Medical Center) Choi, Yoon-Ho (Center for Health Promotion, Samsung Medical Center) Hwang, Jung-Hye (Center for Health Promotion, Samsung Medical Center) |
1 | Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. The Forth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008. Seoul: Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention; 2009 [cited 2011 Oct 23]. Available from: http://knhanes.cdc.go.kr/. |
2 | Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000;2:19-37. DOI |
3 | Zbikowski SM, Swan GE, McClure JB. Cigarette smoking and nicotine dependence. Med Clin North Am 2004;88:1453-65, x. DOI |
4 | Action on Smoking and Health. Smoking statistics: illness and death [Internet]. London: Action on Smoking and Health; 2011 [cited 2011 Oct 23]. Available from: http://www.ash.org.uk/files/documents/ASH_107.pdf. |
5 | Kim IS, Jee SH, Ohrr H, Yi SW. Effects of smoking on the mortality of lung cancer in Korean men. Yonsei Med J 2001;42:155-60. DOI |
6 | Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs 2006;21:433-6. DOI |
7 | Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8. DOI |
8 | Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother 2007;7:121-7. DOI |
9 | Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29:1027-39. DOI |
10 | Kang YS, Choi SY, Ryu E. The effectiveness of a stress coping program based on mindfulness meditation on the stress, anxiety, and depression experienced by nursing students in Korea. Nurse Educ Today 2009;29: 538-43. DOI |
11 | Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997;96:3243-7. DOI |
12 | Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-94. DOI |
13 | Critchley JA, Capewell S. Mortality risk reduction asso ciated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97 DOI |
14 | Enstrom JE, Heath CW Jr. Smoking cessation and mortality trends among 118,000 Californians, 1960-1997. Epidemiology 1999;10:500-12. DOI |
15 | Molyneux A. Nicotine replacement therapy. BMJ 2004; 328:454-6. DOI |
16 | Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296: 47-55. DOI |
17 | Fiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, et al. Methods used to quit smoking in the United States. Do cessation programs help? JAMA 1990;263:2760-5. DOI |
18 | Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 2004;5:55-65. DOI |
19 | Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31: 463-91. DOI |
20 | Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63. DOI |
21 | Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71. DOI |
22 | Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92. DOI |
23 | Song B, Yun WS, Choi EY, Cheong YS, Park EW. Smoking cessation rate and related factors of varenicline in clinical practice. Korean J Fam Med 2011;32: 112-9. DOI |